GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (NAS:RLMD) » Definitions » Price-to-Free-Cash-Flow

Relmada Therapeutics (Relmada Therapeutics) Price-to-Free-Cash-Flow : N/A (As of May. 24, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Relmada Therapeutics Price-to-Free-Cash-Flow?

As of today (2024-05-24), Relmada Therapeutics's share price is $3.11. Relmada Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.60. Hence, Relmada Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Relmada Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

RLMD's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.68
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Relmada Therapeutics's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-0.43. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-1.60.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 1.30% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -8.20% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was -55.90% per year.

During the past 11 years, Relmada Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 33.60% per year. The lowest was -823.50% per year. And the median was -13.45% per year.


Relmada Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Relmada Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relmada Therapeutics Price-to-Free-Cash-Flow Chart

Relmada Therapeutics Annual Data
Trend Aug13 Jun15 Jun16 Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Relmada Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Relmada Therapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Relmada Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relmada Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relmada Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Relmada Therapeutics's Price-to-Free-Cash-Flow falls into.



Relmada Therapeutics Price-to-Free-Cash-Flow Calculation

Relmada Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=3.11/-1.601
=N/A

Relmada Therapeutics's Share Price of today is $3.11.
Relmada Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.60.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Relmada Therapeutics  (NAS:RLMD) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Relmada Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Relmada Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Relmada Therapeutics (Relmada Therapeutics) Business Description

Traded in Other Exchanges
Address
2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Executives
Cedric O'gorman officer: Chief Medical Officer C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES FL 33134
Fabiana Fedeli director C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES FL 33134
Sergio Traversa director, officer: Chief Executive Officer 138 CANTERBURY LN, BLUE BELL PA 19422
Paul Edward Kelly director 300 EAST 56TH STREET, APT 19E, NEW YORK, NY 10022
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027
Maged Shenouda director 305 WEST 18TH STREET, APT 4B, NEW YORK NY 10011
Thomas Wessel officer: EVP, Head of R&D 15 SKYLINE DRIVE, HAWTHORNE NY 10532
Eric Thomas Schmidt director C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John Glasspool director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Chuck Ence officer: Chief Financial Officer 3000 S. UNIVERSITY BLVD., DENVER CO 80210
Ottavio V. Vitolo officer: Chief Medical Officer 71 WESTLAND AVENUE, NEWTON MA 02465
Shreeram Agharkar director P.O BOX 2042, PRINCETON NJ 08543
Sandesh Seth director 300 E 93RD STREET, #20-B, NEW YORK NY 10128
Lisa Nolan officer: Chief Business Officer 36 ROCKLAND MILLS, ROCKLAND DE 19732
Eliseo Oreste Salinas officer: President and CSO 7707 GATEWAY BLVD, NEWARK CA 94560

Relmada Therapeutics (Relmada Therapeutics) Headlines

From GuruFocus